New combo therapy aims to stop leukemia from coming back
NCT ID NCT07539818
First seen May 01, 2026 · Last updated May 01, 2026
Summary
This study tests whether adding venetoclax to azacitidine as maintenance therapy helps keep acute myeloid leukemia (AML) in remission longer. About 788 patients aged 14 to 74 who are in their first remission after initial treatment will receive either azacitidine alone or azacitidine plus venetoclax for up to 12 cycles. The main goal is to see if the combination delays relapse and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.